4-Bromo-2-chloropyridine | CAS:73583-37-6

We serve 4-Bromo-2-chloropyridine CAS:73583-37-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Bromo-2-chloropyridine

Chemical Name:4-Bromo-2-chloropyridine
CAS.NO:73583-37-6
Synonyms:4-Bromo-2-chloropyridine
Molecular Formula:C5H3BrClN
Molecular Weight:192.44100
 
Physical and Chemical Properties:
Density:1.7336
Melting point:27ºC
Boiling point:70ºC
Flash point:225°F
Index of Refraction:1.5900
 
Specification:
Appearance:Gray-white crystal
Assay:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 4-Bromo-2-chloropyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Bromo-2-chloropyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Bromo-2-chloropyridine Use and application,4-Bromo-2-chloropyridine technical grade,usp/ep/jp grade.


Related News: There’s still a lot we don’t know about the coronavirus, and scientists internationally are racing to gather data and develop a treatment.3-iodo-6-nitro-1-(oxan-2-yl)indazole manufacturer Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added “The rigosertib Pre-approval Access Program is a key strategic initiative for Onconova.5-Amino-1,3,4-thiadiazole-2-thiol supplier Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added “The rigosertib Pre-approval Access Program is a key strategic initiative for Onconova.4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methyl morpholinium chloride vendor Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added “The rigosertib Pre-approval Access Program is a key strategic initiative for Onconova.Since the listing of high-barrier generic drugs involves quickly bypassing or challenging process patents of original research products within a short period of time, API companies play an important role in the process of marketing and sales of generic drugs.